Sorry, this version of the site is undergoing maintenance. Please visit on the desktop browser.
2026
The Final Operating System for Pharma
Virtualizing End-to-End Discovery for Small Molecules
We're digitizing pharmaceutical R&D, empowering every chemist and biologist with unified virtual simulations and closed loop experimentation to develop better medicines faster, and with greater precision.
Our Vision
We're building a world where drug discovery is fully digitized, where teams advance candidates from target to clinic through unified simulation and experimentation, without stepping into a lab.
Screening Hit Rate
Less Compounds Synthesized
Months to Hit Package
Less Experiments Ran
Pharma Runs on Revilico OS
Why us?
Our Solutions
We Power Every Phase of Discovery
We're building the singular ecosystem that walks with you all the way to commercialization
Target ID and Validation
Prioritize targets confidently using multi-omics integration and bioinformatics to validate high-confidence targets before committing resources.
Hit Discovery
Rapidly explore chemical space with generative chemistry, virtual screening, and binding prediction to deliver computational hit packages in weeks.
Hit to Lead
Optimize multiple properties simultaneously through integrated quantum chemistry and virtual cell simulations to identify best candidates faster.
Lead Optimization
Balance potency, selectivity, and druglikeness by modeling SAR, predicting off-target effects, and guiding medicinal chemistry with precision.
Wet Lab Testing
Validate computational predictions efficiently through coordinated wet lab testing, closing the loop between in silico design and experimental results.
Why us?
Our Product
The 5 Key Technology Pillars of Revilico OS
We model life at molecular resolution, from small molecules to cells, enabling rational drug design.
Why us?
Our Data
Leverage our Foundational Data Ecosystem
We handle the data integration and curation so you can focus entirely on thinking, discovery, and design.
Unite All Your Experimental and Simulation Data Across Teams
We bridge the gap between computational and experimental scientists.
Use Our AI Agents to Access 100+
Petabytes of Biomedical Data
Sync and Easily Access Databases
You Already Use
What Makes Revilico Different?
We Don't Believe in Incrementally Disrupting the Status Quo.
We are Writing Pharma's Next Era.
End-to-End Tool Ecosystem
We cover all your simulations and experiments from target conception to commercialization.
Fragmented Point Solutions
Every phase transition requires a new solution vendor, partner, or technology.
Competitors
Unified AI and Wet Lab
Advancements are made when DMTA cycles are unified, and data is well communicated.
No Wet-Lab Feedback Loop
Simulations without quick wet lab turnover is just expensive guesswork on a computer.
Virtual Cell Models
The next paradigm of computational drug design is simulating ligand-cell interactions.
Hit to Lead Restricted Tools
Majority of tools are bioinformatics tools for target ID or ligand protein interaction simulation.
Accessible Economics
We believe that SOTA tools democratized for everyone benefits the entire ecosystem.
Enterprise only Pricing
Many high performing algorithms are restricted to pricey, enterprise only contracts.
3-Pronged Data Ecosystem
Access our curated knowledge base, your experimentation, and your computation.
Limited Data Access
Restricted to experimental organization, or pure computational data and algorithms.
Chemistry and Biology Suite
We simulate compounds, proteins, and large cell systems at high fidelity.
Limited Technology Scope
Several technologies are restricted to highly specific vertical use cases.
FAQs
Answers to Your Most Common Questions
Everything you need to know about getting started, using the platform, and unlocking its full potential.
What problem does Revilico solve?
Drug discovery today is fragmented and inefficient. Scientists juggle massive datasets, multiple tools, and manual workflows slowing innovation. Revilico unifies these tools under one OS, allowing for centralized data, guided AI agents, and seamless wet-lab translation
Why is now the right time for this technology?
Pharma is undergoing a radical digital transformation. With 40% of patents expiring by 2030 and $180B in revenue at risk, companies are under pressure to innovate. Revilico’s timing coincides with advancements in AI, cloud computing, and multi-omics integration enabling unprecedented efficiency and discovery potential
How does the Revilico platform work?
The OS integrates core engines Docking, Co-folding, Molecular Dynamics (MD), FEP+, Generative and Quantum Chemistry, and Virtual Cells, to cover the full spectrum of drug discovery, from Target ID to Preclinical Development
What makes Revilico different from traditional tools?
Unlike fragmented computational pipelines, Revilico unifies centralized multi-omic datasets, AI-driven workflow automation, GPU-accelerated algorithms that run 70× faster than traditional docking, and integrated wet-lab validation with virtual cell simulations.
What is “Virtual Cell”?
Virtual Cell is an AI co-pilot for wet-lab screening. It simulates cellular pathways and predicts drug-cell interactions. helping researchers identify promising compounds early and reduce costly lab experiments. We use both data driven techniques and physics based pathway propagation models to predict perturbed phenotypes.
What is Revilico's "Data Ecosystem"?
Revilico’s proprietary data infrastructure harmonizes 330M single cells, 70B+ compounds, 246M+ proteins, 47M+ articles, and 464k clinical trials into a structured database. It unifies fragmented public and proprietary data into one interoperable ecosystem, driving faster and smarter drug design.
How has Revilico been validated?
Read more about specific case studies we have run on our resources page. Revilico’s predictions and experimental bioactivities show high correlation across multiple targets. The company has validated compounds across several cancer targets and co-developed pipelines in oncology, immunology, and CNS indications
How does Revilico ensure accuracy?
Computational tools are a powerful resource to help test, validate, and explore hypotheses exceptionally quickly to cut down on experimental waste. Before moving forward with experimentation, we always calibrate our algorithms for your system to ensure you choose the right algorithm suitable for your systems.
What results has Revilico achieved?
Revilico achieves a 3× higher hit rate (80–90% vs. 30–50%) for target validation, reduces compound screening by over 98% with a nearly 5% hit rate, accelerates DMTA cycles by 75–83%, and lowers IND costs by 60–75% (from $27M to $7–10M).
How does Revilico compare to competitors?
Revilico offers a true end-to-end OS with Virtual Cells, multi-omic integration, quantum chemistry, and robotic automation, capabilities competitors treat as separate modules. It democratizes access with a user-friendly, cloud-scaled interface.
How do I get started?
Just click Join Now and sign up for an account. Revilico provides white-glove onboarding, personalized setup, and guided training to help you get started immediately, or you can book a meeting with our team for a tailored walkthrough.
What happens after I get an account?
Revilico offers comprehensive training, detailed documentation, and ongoing support resources to help every user quickly learn, build, and scale their projects with confidence. We believe that a large part of the process is teaching those using the tools how to interpret, calibrate, and gain intuition on the simulations.
Sorry, this version of the site is undergoing maintenance. Please visit on the desktop browser.
The Final Operating System of Pharma.
The Final Operating System of Pharma.
The Final Operating System of Pharma.